Seamus Fernandez
Stock Analyst at Guggenheim
(4.96)
# 102
Out of 4,595 analysts
415
Total ratings
65.7%
Success rate
31.2%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $72 → $75 | $65.31 | +14.84% | 50 | Jul 31, 2026 | |
| ARQT Arcutis Biotherapeutics | Reiterated: Buy | $35 | $26.86 | +30.31% | 14 | Jul 16, 2026 | |
| PCVX Vaxcyte | Maintained: Buy | $116 | $54.08 | +114.50% | 13 | Jul 14, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $88 | $65.93 | +33.47% | 15 | Jul 14, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,235 → $1,273 | $1,148.84 | +10.81% | 62 | Jul 13, 2026 | |
| SNY Sanofi | Maintained: Hold | n/a | $43.08 | - | 13 | Jul 9, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p → 16,200p | 12,632p | +28.25% | 20 | Jul 9, 2026 | |
| SEPN Septerna | Reiterated: Buy | $52 → $45 | $34.45 | +30.62% | 2 | Jul 1, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $30 → $40 | $20.31 | +96.95% | 9 | Jun 26, 2026 | |
| GENB Generate Biomedicines | Reiterated: Buy | $30 | $14.00 | +114.29% | 3 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $134.09 | - | 12 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 → $40 | $13.70 | +191.97% | 6 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $143 | $99.25 | +44.08% | 13 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $4.48 | +145.54% | 6 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $48 | $25.52 | +88.09% | 8 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.76 | - | 10 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $5.20 | +130.77% | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 | $48.04 | +191.42% | 7 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $7.11 | +251.62% | 4 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €110.00 → €101.00 | €74.47 | +35.63% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $47.08 | n/a | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.84 | n/a | 12 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 1,013 → kr 798.00 | kr 327.25 | n/a | 4 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $51.69 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,931.50 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 → $130 | $130.20 | n/a | 36 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $250 → $83 | $18.27 | n/a | 5 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.535 | n/a | 2 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $143.15 | n/a | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $126.60 | n/a | 4 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $156.15 | n/a | 16 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $4.95 | n/a | 1 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.96 | n/a | 2 | Sep 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $37 | $25.01 | n/a | 16 | Sep 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $12.49 | n/a | 1 | Aug 24, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $6.73 | n/a | 3 | Aug 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $205.52 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $385.16 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $762.63 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $256.35 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $56 | $30.02 | n/a | 5 | Jun 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 | $38.06 | n/a | 1 | Mar 7, 2016 |
Bristol-Myers Squibb Company
Jul 31, 2026
Reiterated: Buy
Price Target: $72 → $75
Current: $65.31
Upside: +14.84%
Arcutis Biotherapeutics
Jul 16, 2026
Reiterated: Buy
Price Target: $35
Current: $26.86
Upside: +30.31%
Vaxcyte
Jul 14, 2026
Maintained: Buy
Price Target: $116
Current: $54.08
Upside: +114.50%
MBX Biosciences
Jul 14, 2026
Reiterated: Buy
Price Target: $88
Current: $65.93
Upside: +33.47%
Eli Lilly and Company
Jul 13, 2026
Rated: Buy
Price Target: $1,235 → $1,273
Current: $1,148.84
Upside: +10.81%
Sanofi
Jul 9, 2026
Maintained: Hold
Price Target: n/a
Current: $43.08
Upside: -
AstraZeneca PLC
Jul 9, 2026
Reiterated: Buy
Price Target: 16,500p → 16,200p
Current: 12,632p
Upside: +28.25%
Septerna
Jul 1, 2026
Reiterated: Buy
Price Target: $52 → $45
Current: $34.45
Upside: +30.62%
Amylyx Pharmaceuticals
Jun 26, 2026
Reiterated: Buy
Price Target: $30 → $40
Current: $20.31
Upside: +96.95%
Generate Biomedicines
Jun 24, 2026
Reiterated: Buy
Price Target: $30
Current: $14.00
Upside: +114.29%
Jun 23, 2026
Downgraded: Hold
Price Target: n/a
Current: $134.09
Upside: -
Jun 22, 2026
Maintained: Buy
Price Target: $34 → $40
Current: $13.70
Upside: +191.97%
Jun 15, 2026
Reiterated: Buy
Price Target: $143
Current: $99.25
Upside: +44.08%
May 27, 2026
Reiterated: Buy
Price Target: $11
Current: $4.48
Upside: +145.54%
May 18, 2026
Maintained: Buy
Price Target: $48
Current: $25.52
Upside: +88.09%
May 11, 2026
Maintained: Hold
Price Target: n/a
Current: $5.76
Upside: -
May 11, 2026
Reiterated: Buy
Price Target: $12
Current: $5.20
Upside: +130.77%
May 7, 2026
Maintained: Buy
Price Target: $140
Current: $48.04
Upside: +191.42%
Apr 29, 2026
Reiterated: Buy
Price Target: $27 → $25
Current: $7.11
Upside: +251.62%
Oct 8, 2025
Maintained: Buy
Price Target: €110.00 → €101.00
Current: €74.47
Upside: +35.63%
Apr 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $47.08
Upside: n/a
Apr 3, 2025
Rated: Hold
Price Target: n/a
Current: $2.84
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: kr 1,013 → kr 798.00
Current: kr 327.25
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $51.69
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $1,931.50
Upside: n/a
Jan 29, 2024
Maintained: Buy
Price Target: $125 → $130
Current: $130.20
Upside: n/a
Oct 14, 2022
Maintained: Buy
Price Target: $250 → $83
Current: $18.27
Upside: n/a
Dec 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.535
Upside: n/a
Dec 7, 2021
Downgraded: Hold
Price Target: n/a
Current: $143.15
Upside: n/a
Feb 25, 2020
Downgraded: Hold
Price Target: n/a
Current: $126.60
Upside: n/a
Oct 8, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $156.15
Upside: n/a
Oct 17, 2017
Initiated Coverage: Buy
Price Target: $13
Current: $4.95
Upside: n/a
Sep 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $3.96
Upside: n/a
Sep 8, 2016
Maintained: Hold
Price Target: $37
Current: $25.01
Upside: n/a
Aug 24, 2016
Reiterated: Buy
Price Target: $108
Current: $12.49
Upside: n/a
Aug 9, 2016
Reiterated: Buy
Price Target: $52
Current: $6.73
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $205.52
Upside: n/a
Jul 15, 2016
Rated: Hold
Price Target: n/a
Current: $385.16
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $762.63
Upside: n/a
Jun 14, 2016
Maintained: Buy
Price Target: $125
Current: $256.35
Upside: n/a
Jun 13, 2016
Reiterated: Hold
Price Target: $56
Current: $30.02
Upside: n/a
Mar 7, 2016
Downgraded: Hold
Price Target: $4
Current: $38.06
Upside: n/a